id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2582-0007,FDA,FDA-2015-E-2582,Determination of Regulatory Review Period for Purposes of Patent Extension; STRIVERDI RESPIMAT,Notice,Determinations,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,2018-02-27T04:59:59Z,2017-12-26T16:25:50Z,2017-27710,0,0,0900006482d727f7
FDA-2015-E-2582-0006,FDA,FDA-2015-E-2582,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-05T04:00:00Z,2017,6,2017-06-05T04:00:00Z,,2017-06-05T19:36:52Z,,0,0,09000064826929b0
FDA-2015-E-2582-0005,FDA,FDA-2015-E-2582,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-04-07T04:00:00Z,2017,4,2017-04-07T04:00:00Z,,2017-04-07T14:16:49Z,,0,0,0900006482542f45
FDA-2015-E-2582-0004,FDA,FDA-2015-E-2582,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-11-23T05:00:00Z,2016,11,2016-11-23T05:00:00Z,,2016-11-23T12:47:43Z,,0,0,09000064823b9436
FDA-2015-E-2582-0003,FDA,FDA-2015-E-2582,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-10-15T04:00:00Z,2015,10,2015-10-15T04:00:00Z,,2015-10-15T20:19:26Z,,0,0,0900006481ccf1e3
FDA-2015-E-2582-0001,FDA,FDA-2015-E-2582,Patent Extension Application from  Boehringer Ingelheim USA Corp (on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG ),Other,Application,2015-07-21T04:00:00Z,2015,7,2015-07-21T04:00:00Z,,2015-07-21T15:22:51Z,,0,0,0900006481b94f78
FDA-2015-E-2582-0002,FDA,FDA-2015-E-2582,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-07-21T04:00:00Z,2015,7,2015-07-21T04:00:00Z,,2015-07-21T15:22:59Z,,0,0,0900006481b94881